DEF 14C: Cyclacel Pharmaceuticals Approves Reverse Stock Split to Maintain Nasdaq Listing and Boost Market Profile

Cyclacel Pharmaceuticals, Inc. has announced the approval of a reverse stock split by its majority stockholder and Board of Directors, aiming to increase its share price to meet Nasdaq listing requirements and enhance marketability.

Summary

• Cyclacel Pharmaceuticals, Inc. (the Company) is furnishing an Information Statement (DEF 14C) to inform stockholders of actions taken by written consent of the Majority Consenting Stockholder on May 12, 2025.
• The approved action is an amendment to the Company's Certificate of Incorporation to effect a reverse stock split of all outstanding common stock.
• The reverse stock split ratio will be between one-for-three (1:3) and one-for-hundred (1:100), to be determined at the Board's sole discretion.
• The Majority Consenting Stockholder, Datuk Dr. Doris Wong Sing Ee (CEO), holding 12,164,301 shares or approximately 54.6% of voting power, approved the action.
• The Board of Directors unanimously approved the reverse stock split and the associated amendment.
• As of May 12, 2025, the Company had 22,272,346 shares of common stock outstanding.
• As of May 22, 2025, the Company had 23,759,475 shares of common stock outstanding, with a closing price of $1.45 on Nasdaq and a total market value of approximately $34,451,238.75.
• The reverse stock split will not change the number of authorized shares (600,000,000) or the par value ($0.001 per share).
• Fractional shares resulting from the split will be rounded up to the next whole number, with no cash paid in lieu of fractional shares.
• The action will not be implemented until at least 20 days after the Information Statement is first mailed to stockholders (on or about May 23, 2025), making the earliest effective date June 12, 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While a reverse stock split often carries a negative perception, the company explicitly states its strategic reasons (Nasdaq compliance, marketability, attracting investors) and frames it as a necessary step for future growth and opportunities. The approval by a majority stockholder and the board indicates internal alignment. However, the inherent risks of a reverse split (no guaranteed price increase, liquidity concerns, anti-takeover effects) temper the overall positive outlook.

Positives

• The reverse stock split is intended to increase the Company's stock price to meet Nasdaq Capital Market's minimum bid price requirements, preventing delisting.
• It aims to make the Common Stock more attractive to a broader range of institutional and other investors, potentially increasing marketability and liquidity.
• A higher stock price could increase the Company's profile for private investment, acquisitions, and other future opportunities.
• The Board believes it will better position the Company to attract potential business candidates and provide stockholders a greater potential return.
• The process used (written consent) is more efficient, reducing costs and management time compared to holding a special stockholders' meeting.

Negatives

• There is no assurance that the reverse stock split will result in a proportionate increase or any increase in the stock price on Nasdaq.
• The reduction in outstanding shares could adversely affect the trading market by reducing the relative level of liquidity.
• The Company's aggregate market capitalization could be reduced if the price increase is proportionately less than the decrease in shares outstanding.
• There is a negative perception of reverse stock splits among some stock market participants.
• The increased proportion of unissued authorized shares after the split could have an anti-takeover effect, potentially diluting existing ownership or hindering changes in control.

Risks

• The market price of the Common Stock after the reverse stock split may not increase in proportion to the decrease in outstanding shares, or may not increase at all.
• Any increase in stock price may not be sustained for a prolonged period of time.
• The reverse stock split may not enhance the liquidity of, or investor interest in, the Common Stock.
• The availability of a significant number of authorized but unissued shares after the split could be used to dilute existing stockholders' interests in future capital-raising or acquisition transactions.
• The additional shares could be used by management to oppose hostile takeover attempts or delay changes in control.

Future Outlook

The Company anticipates that the reverse stock split, if implemented, will help maintain compliance with Nasdaq's minimum bid price requirement, potentially increase the stock's market price, enhance marketability and liquidity, and attract a broader range of investors. It also aims to better position the Company for future private investment, acquisitions, and other business opportunities.

Management Comments

• "The Written Consent authorized the Company's board of directors (the Board) to amend the Company's amended and restated certificate of incorporation, as amended (the Certificate of Incorporation) to effect a reverse stock split of all outstanding shares of Common Stock, by a ratio that will not be less than one-for-three (1:3) or exceed a ratio of one-for-hundred (1:100) (the Approved Split Ratios), to be determined in the Board's sole discretion."
• "The Board believes that the stockholders of the Company will benefit from the Reverse Stock Split because it believes that such Reverse Stock Split could be a catalyst for an increase in the stock price of the Common Stock, which in turn could increase the marketability and liquidity of the Company's Common Stock, as well as increase the profile of the Company for private investment, acquisitions and other future opportunities that become available to the Company."
• "Accordingly, it is the Board's opinion that the Reverse Stock Split and the Reverse Stock Split Amendment, would better position the Company to attract potential business candidates and provide the stockholders a greater potential return."
• "Our board of directors determined to pursue stockholder action by majority written consent of those shares entitled to vote in an effort to reduce the costs and management time required to hold a special meeting of stockholders and to implement the above action in a timely manner."
• "The Company believes that if implemented, the Reverse Stock Split and the Reverse Stock Split Amendment, will benefit all stockholders, as without the Reverse Stock Split and the Reverse Stock Split Amendment, the Company may have difficulties maintaining compliance with the listing requirements of Nasdaq."

Industry Context

This announcement reflects a common strategy employed by companies, particularly those listed on exchanges like Nasdaq, to maintain compliance with minimum bid price requirements. A reverse stock split is often used when a company's stock price has fallen significantly, risking delisting. By increasing the per-share price, Cyclacel aims to improve its standing with institutional investors who may have policies against investing in 'penny stocks' and to enhance its overall market perception, aligning with broader market expectations for listed companies.

Comparison to Industry Standards

• Many companies facing Nasdaq's minimum bid price requirement (Rule 5550(a)(2)) resort to reverse stock splits as a primary mechanism to regain compliance. This is a standard practice in the industry for maintaining listing status.
• The proposed ratio range of 1:3 to 1:100 is broad, providing the Board significant flexibility, which is typical for such authorizations, allowing them to react to market conditions closer to the implementation date.
• The stated goals of increasing marketability, liquidity, and attracting institutional investors are common objectives for companies undertaking reverse splits, as lower-priced stocks often face higher brokerage commissions and less analyst coverage, which can deter larger investors.

Corporate Governance

Related Party Transactions

• Datuk Dr. Doris Wong Sing Ee, the Company's Chief Executive Officer and Executive Director, is the sole Majority Consenting Stockholder, holding 12,164,301 shares (approximately 54.6%) of the Company's outstanding Common Stock. She approved the reverse stock split by written consent.

Stakeholder Impact

• **Shareholders**: Will own a reduced number of shares but their percentage ownership will remain unchanged (except for fractional share rounding). The goal is to increase the per-share price, potentially improving marketability and attracting new investors. However, there's no guarantee of a sustained price increase or improved liquidity.
• **Management/Board**: The Board gains discretion to implement the split and potentially use authorized shares for future corporate actions, including capital raises, without further stockholder approval. The CEO, as the majority stockholder, has significant control over corporate actions.
• **Nasdaq**: The action is intended to maintain compliance with Nasdaq's minimum bid price requirement, benefiting the Company's listing status.

Next Steps

• The Information Statement will be first distributed to stockholders on or about May 23, 2025.
• The reverse stock split will not be implemented until at least 20 days after the mailing date of the Information Statement (no earlier than June 12, 2025).
• The Board of Directors will determine the exact ratio of the reverse stock split (within 1:3 to 1:100) and publicly announce it prior to filing the amendment.
• The Company will file a Certificate of Amendment to its Certificate of Incorporation with the State of Delaware to effect the split.
• The Company will submit a Corporate Event Notification Form to Nasdaq and take appropriate actions to comply with Nasdaq Rule 5250(e)(7).
• The Board reserves the right to abandon the proposed reverse stock split amendment at any time before its effectiveness if it deems it not in the best interests of the Company and stockholders.

Key Dates

Keywords

Cyclacel Pharmaceuticals, Reverse Stock Split, Nasdaq Listing Compliance, SEC Filing, DEF 14C, Corporate Governance, Stock Market, Share Price, Liquidity, Capital Market